Adamis Pharmaceuticals Corporation announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities: David J. Marguglio, Co-Founder and Chief Business Officer, has been appointed as Chief Executive Officer, effective immediately. Dennis J. Carlo, Ph.D., has retired from the Chief Executive Officer role, effective immediately. Mr. Marguglio will continue his director role, and a search has commenced to identify a highly qualified and independent director to fill the vacancy resulting from Dr. Carlo's retirement from the Company.

Richard C. Williams, Chairman of the Board, added, “After carefully considering the right successor for Dennis, who provided strong leadership over many years, the Board has determined that David is the ideal leader for Adamis at this pivotal inflection point. David has the right balance of institutional knowledge and new ideas for driving value. He is also a proven operator with a firm understanding of bringing drugs and treatments from concept to commercialization.